JP2019500346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500346A5 JP2019500346A5 JP2018529237A JP2018529237A JP2019500346A5 JP 2019500346 A5 JP2019500346 A5 JP 2019500346A5 JP 2018529237 A JP2018529237 A JP 2018529237A JP 2018529237 A JP2018529237 A JP 2018529237A JP 2019500346 A5 JP2019500346 A5 JP 2019500346A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- peroxisome proliferator
- activated receptor
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022013876A JP2022062143A (ja) | 2015-12-14 | 2022-02-01 | 腎臓病の処置のための組成物と方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267242P | 2015-12-14 | 2015-12-14 | |
| US62/267,242 | 2015-12-14 | ||
| PCT/US2016/066576 WO2017106292A1 (en) | 2015-12-14 | 2016-12-14 | Compositions and methods for treatment of kidney diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013876A Division JP2022062143A (ja) | 2015-12-14 | 2022-02-01 | 腎臓病の処置のための組成物と方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500346A JP2019500346A (ja) | 2019-01-10 |
| JP2019500346A5 true JP2019500346A5 (enExample) | 2020-01-30 |
| JP7049247B2 JP7049247B2 (ja) | 2022-04-06 |
Family
ID=59057520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529237A Expired - Fee Related JP7049247B2 (ja) | 2015-12-14 | 2016-12-14 | 腎臓病の処置のための組成物と方法 |
| JP2022013876A Pending JP2022062143A (ja) | 2015-12-14 | 2022-02-01 | 腎臓病の処置のための組成物と方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013876A Pending JP2022062143A (ja) | 2015-12-14 | 2022-02-01 | 腎臓病の処置のための組成物と方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3390666A4 (enExample) |
| JP (2) | JP7049247B2 (enExample) |
| CA (1) | CA3005249A1 (enExample) |
| WO (1) | WO2017106292A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| EP3201339A4 (en) | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
| AU2016334804B2 (en) | 2015-10-09 | 2022-03-31 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| ES2882500T3 (es) | 2015-12-14 | 2021-12-02 | Cold Spring Harbor Laboratory | Oligómeros antisentido para el tratamiento del síndrome de Dravet |
| SG11201906735RA (en) | 2017-01-23 | 2019-08-27 | Regeneron Pharma | Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof |
| JP2020516283A (ja) | 2017-04-11 | 2020-06-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヒドロキシステロイド（１７−ベータ）デヒドロゲナーゼ（ｈｓｄ１７ｂ）ファミリーのメンバーのモジュレーターの活性をスクリーニングするためのアッセイ |
| SI3673080T1 (sl) | 2017-08-25 | 2024-03-29 | Stoke Therapeutics, Inc. | Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni |
| KR20240125690A (ko) | 2017-10-11 | 2024-08-19 | 리제너론 파마슈티칼스 인코포레이티드 | Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해 |
| CN112020556A (zh) | 2018-03-21 | 2020-12-01 | 瑞泽恩制药公司 | 第13型17β羟基类固醇脱氢酶(HSD17B13)iRNA组成物及其使用方法 |
| WO2019213525A1 (en) | 2018-05-04 | 2019-11-07 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| US12163129B2 (en) | 2018-06-08 | 2024-12-10 | University Of Massachusetts | Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells |
| JP7619939B2 (ja) | 2018-10-05 | 2025-01-22 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 原発性免疫不全症、シスチン症、及びウィルソン病に関する新生児スクリーニング |
| US20220090087A1 (en) * | 2019-01-23 | 2022-03-24 | The Florey Institute Of Neuroscience And Mental Health | Antisense oligonucleotides targeting scn2a retained introns |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| CA3147970A1 (en) * | 2019-08-19 | 2021-02-25 | Isabel AZNAREZ | Compositions and methods for modulating splicing and protein expression |
| EP4126966A4 (en) | 2020-03-31 | 2024-08-07 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | PROTEOMIC SCREENING FOR LYSOSOMAL STORAGE DISEASES |
| US12523662B2 (en) | 2020-04-02 | 2026-01-13 | Seattle Children's Hospital | Antibodies that specifically bind peptides associated with the primary immunodeficiencies: Wiskott-Aldrich syndrome and x-linked agammaglobulinemia |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030224514A1 (en) * | 2002-05-31 | 2003-12-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PPAR-delta expression |
| CA2588646A1 (en) * | 2004-11-19 | 2006-05-26 | Acadia Pharmaceuticals Inc. | Methods to identify ligands of hormone nuclear receptors |
| US20110269735A1 (en) * | 2010-04-19 | 2011-11-03 | Celera Corporation | Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof |
| US20140128449A1 (en) * | 2011-04-07 | 2014-05-08 | The Board Of Regents Of The University Of Texas System | Oligonucleotide modulation of splicing |
| US9909128B2 (en) * | 2012-11-15 | 2018-03-06 | The Regents Of The University Of California | Splice modulating oligonucleotides that inhibit cancer |
| ES2779302T3 (es) * | 2013-09-04 | 2020-08-14 | Cold Spring Harbor Laboratory | Reducción de la degradación de ARNm con mediación sin sentido |
| EP3201339A4 (en) * | 2014-10-03 | 2018-09-19 | Cold Spring Harbor Laboratory | Targeted augmentation of nuclear gene output |
-
2016
- 2016-12-14 CA CA3005249A patent/CA3005249A1/en active Pending
- 2016-12-14 WO PCT/US2016/066576 patent/WO2017106292A1/en not_active Ceased
- 2016-12-14 EP EP16876548.5A patent/EP3390666A4/en not_active Withdrawn
- 2016-12-14 JP JP2018529237A patent/JP7049247B2/ja not_active Expired - Fee Related
-
2022
- 2022-02-01 JP JP2022013876A patent/JP2022062143A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501892A5 (enExample) | ||
| JP2019500347A5 (enExample) | ||
| JP2019500349A5 (enExample) | ||
| JP2018538288A5 (enExample) | ||
| JP2018538287A5 (enExample) | ||
| JP2024056778A5 (enExample) | ||
| JP2019500350A5 (enExample) | ||
| US20230203483A1 (en) | Compositions and Methods Using SNRNA Components | |
| JP2017536338A5 (enExample) | ||
| AU2017379073B2 (en) | Compositions and methods for treating alpha-1 antitrypsin deficiency | |
| EP2027267B1 (en) | Means and method for inducing exon-skipping | |
| CN107406852B (zh) | 用于莱伯氏先天性黑蒙的寡核苷酸疗法 | |
| AU2010335039B2 (en) | Molecule for treating an inflammatory disorder | |
| KR20080031164A (ko) | ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절 | |
| CN113195721A (zh) | 治疗α-1抗胰蛋白酶缺乏症的组合物和方法 | |
| EP3353301A1 (en) | Antisense oligonucleotides and uses thereof | |
| US20200407721A1 (en) | Compounds of chemically modified oligonucleotides and methods of use thereof | |
| JP2021523227A5 (enExample) | ||
| JP7760130B2 (ja) | Ａｐｏｃ３を標的としたアンチセンス核酸 | |
| Benchaouir et al. | Splicing modulation mediated by small nuclear RNAs as therapeutic approaches for muscular dystrophies | |
| US20250327093A1 (en) | Viral vector and cancer cell proliferation inhibitor comprising the same | |
| EP3690046A2 (en) | Composition for treatment of hemophilia, comprising crispr/cas system having coagulation factor viii gene inversion correction potential | |
| CA2999192C (en) | Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof | |
| KR20250122542A (ko) | 넌센스 매개 rna 분해 기반 병태 및 질환의 치료를 위한 안티센스 올리고머 | |
| WO2021158810A1 (en) | Oligonucleotides for splice modulation of camk2d |